Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis.

Donald C MooreKeren A EagersAmanda JanesMauricio Pineda-Roman

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

The combination of tafasitamab and dose-reduced lenalidomide produced a complete response in the treatment of relapsed/refractory diffuse large B-cell lymphoma in the setting of chronic intermittent hemodialysis.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
multiple myeloma
end stage renal disease
peritoneal dialysis
chronic kidney disease
high intensity
newly diagnosed
stem cell transplantation
case report
acute myeloid leukemia
combination therapy
drug induced